Developer docs
API playgroundTry for free, no card

Search company profiles

BIOS

Full company profile

uuid0000ntm

Namestring
BIOS
Legal namestring
BIOS Health Ltd
Websiteurl
bios.health
Company typeenum
Private
Founded yearint
2015
Descriptiontext

BIOS Health Ltd is a Cambridge, UK-based neural engineering company founded in 2015 by Cambridge University researchers Emil Hewage and Oliver Armitage. The company develops AI-driven neural interface technology that reads and writes the body's neural signals in real-time, with the stated goal of building "neural digital therapies" as a new class of precision medicine. Its core platform combines proprietary neural interfaces with machine learning, including Bayesian optimization (NeuroTune), neural biomarker discovery, and a Remote Health Platform that pairs wearables with mobile apps to capture cardiac and autonomic biomarkers. The technology is positioned as functionally analogous to DNA sequencing for the nervous system, supporting personalized neuromodulation dosing and software-delivered therapies for chronic cardiovascular, neurological, and metabolic conditions.

BIOS serves pharmaceutical companies, medical device manufacturers (particularly neuromodulation device makers), healthcare providers, and academic medical centers. Revenue is generated through long-term co-development partnerships (subscription/recurring), clinical trial data services (professional services), and licensing of the NeuroTune platform, with multi-year contracts and quote-based pricing disclosed as the standard engagement model. The company is supported by a deep research and grant ecosystem spanning NIH (REVEAL $21M project), SPARC-NIH ($1.4M grant plus Neuromod Prize), Canadian collaborations with Mila/McGill/Universit\u00e9 de Montr\u00e9al (cumulative CA$2.6M), the NHS, and a board chaired by IQVIA's VP of Genomic and Precision Medicine. Operationally, BIOS maintains hubs in Cambridge (headquarters), Montreal (AI R&D at Mila), and Bakersfield, California (US clinical and commercial hub established January 2024), and in 2026 spun out a majority-owned subsidiary, Kordata Dynamics, to commercialize an AI-powered precision clinical trials platform built on BIOS's NeuroTune IP.

Short descriptiontext

BIOS Health is a UK-based neural engineering company that builds AI-driven neural interfaces and an AI dosing platform (NeuroTune) to read and write the body's nervous system signals in real time, serving pharmaceutical firms, neuromodulation device makers, healthcare providers, and academic medical centers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neural digital therapies, neuromodulation dosing AI, bioelectronic medicine, neural biomarker discovery, autonomic therapy platform
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Neural Engineering / Bioelectronic Medicine Software
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Technology Partnerships with Pharma/MedTech
TypeSubscription Recurring
Description

Long-term partnerships for co-development of neural digital therapies with pharmaceutical and medical device companies. BIOS technology enables real-time insights into how pharmaceuticals affect the nervous system, cutting feedback time on efficacy results from months to minutes.

bios.health
2Clinical Trial Services
TypeProfessional Services
Description

Providing neural data analysis services for clinical trials, enabling pharmaceutical companies to reduce trial timelines and improve success rates through real-time neural response monitoring.

bios.health
3NeuroTune Platform Licensing
TypeLicensing Royalties
Description

Making BIOS NeuroTune available to select clinical and preclinical partners for personalized dosing optimization of neuromodulation devices.

bios.health
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
Pricing details1 tier
1Enterprise partnership model - custom pricing based on scope
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Long-term partnerships for co-development of neural digital therapies. BIOS NeuroTune available to select clinical and preclinical partners. Quote-based pricing.

bios.health
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1NeuroTune
Description

BIOS NeuroTune is the company's dosing AI co-pilot that personalizes neuromodulation device settings in under ten minutes. The algorithms dynamically model a patient or subject's neural and physiological responses to stimulations and suggest personalized parameters.

bios.health
+2 more records
Core offering1 text field

BIOS Health develops an AI-driven neural interface platform that reads and writes nervous system signals in real-time to enable neural digital therapies. The company sells co-development partnerships, clinical trial data services, and licensing of its NeuroTune dosing AI platform to pharmaceutical, medical device, and clinical research partners, with a primary focus on autonomic and neuromodulation therapies for chronic diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Reduces neuromodulation device optimization from 12 months to under 10 minutes
+3 more records
Product and service5 records
1NeuroTune (Neural Dosing Platform)
CategoryAI Dosing Software
Description

AI-powered dosing co-pilot that personalizes neuromodulation device settings in under 10 minutes. Dynamically models patient neural and physiological responses to stimulations and suggests personalized parameters. For researchers, accelerates therapy discovery by assessing thousands of unique stimulations in a single trial.

2Neural Biomarker Discovery Platform
CategoryNeural Biomarker Analysis
Description

Technology platform that precisely links nerve activity to specific chronic conditions by isolating neural biomarkers of disease and responding to them in real-time. Enables reading and writing the body's neural signals to understand and correct faulty signals causing disease.

3Remote Health Platform (RHP)
CategoryRemote Patient Monitoring
Description

Medical device platform combining wearable devices and mobile apps to monitor patient health remotely. Collects biomarkers and cardiac metrics including ECG, PPG, accelerometer, respiratory pressure, and blood glucose data to deliver personalized and responsive neural digital therapies.

4Autonomic Therapy Initiative (ATI)
CategoryCardiovascular Neural Therapy Programme
Description

Programme initiative to develop neural digital therapies for cardiovascular diseases using AI-powered neural interfaces. Works with world-leading partners to deliver new treatments for heart disease through real-time neural signal analysis and closed-loop neuromodulation.

5Clinical Trial Neural Data Services
CategoryClinical Research Services
Description

Service offering that provides neural data analysis for pharmaceutical clinical trials, enabling real-time neural response monitoring, adaptive dosing optimization, and reduced trial timelines by cutting efficacy feedback time from months to minutes.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership18 partners
1City of Bakersfield
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-08
Description

Partnered with KVG and Kern County to establish BIOS West Coast precision medicine hub. Approved $250K grant for BIOS to establish first US clinical and commercial hub.

govtech.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-08
Description

Partnered with City of Bakersfield and KVG to attract BIOS to the region. Part of economic development initiative for biotech and AI sector growth.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-06-22
Description

Partnership to develop trained workers for BIOS precision medicine hub in Bakersfield.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-11-03
Description

BIOS technology selected to power the $21M REVEAL project - the largest ever single clinical study of human neural data. BIOS provides software infrastructure for analyzing neural data from 150 patients across 8 global clinics over 3 years, investigating neural therapies for chronic diseases.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-11-03
Description

Lead institution for NIH REVEAL project. Principal Investigator John Osborn leads the consortium. Study focuses on vagus nerve physiology and neural therapies for cardiovascular, metabolic, immune, and autonomic nervous systems.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-03
Description

Clinical partner in REVEAL project, contributing to research on neural therapies for chronic diseases including heart failure, epilepsy, and respiratory conditions.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-03
Description

Clinical partner in NIH REVEAL project, contributing expertise to neural biomarker research and vagus nerve stimulation therapies.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-11-03
Description

Academic health system partner in REVEAL consortium for neural therapies research.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-11-03
Description

Academic partner in NIH REVEAL project consortium.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-11-03
Description

Mental health system partner in REVEAL project consortium.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-11-03
Description

European academic partner in REVEAL project for vagus nerve research.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-11-03
Description

Australian research partner in REVEAL consortium for neural-cardiac research.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-05-26
Description

BIOS opened R&D office at Mila in 2018 to leverage Montreal's AI talent. Partnership to develop AI-controlled closed-loop neuromodulation system for chronic cardiac conditions. Extended in 2022 with CA$1.8M funding.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-05-26
Description

Research partnership with Dr. Blake Richards (School of Computer Science) to use machine learning to identify relationships between cardiac activity and neural signals. Part of CA$800K and CA$1.8M initiatives.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-05-26
Description

Research partnership with Dr. Guillaume Lajoie (Applied Mathematics) to optimize neural interface system for decoding and encoding brain-to-body signals. Part of neuro-cardiology AI collaboration.

Strategic tierCoreTypeTechnology or Integration
Description

NVIDIA GPUs used for BIOS AI and machine learning processing. Listed as selected partner on website footer.

17NHS
Strategic tierCoreTypeStrategic or Co-development Partner
Description

UK National Health Service partnership for clinical trials. BIOS conducted remote trials with NHS during COVID-19 pandemic.

bios.health
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

NIH Common Fund program. Awarded BIOS $1.4M grant in 2021 and BIOS won $100K Neuromod Prize Phase 1. BIOS technology powers SPARC objectives for neural treatment development.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Synchron develops brain-computer interface technology (Stentrode) for patients with paralysis, similar to BIOS's neural interface focus. Both target chronic disease through neural signal interpretation, though Synchron emphasizes motor restoration while BIOS targets therapy dosing and digital therapeutics.

TypeDirect peer
Description

Blackrock Neurotech builds neural interface platforms for research and clinical applications, with similar focus on reading/writing neural signals. Both companies pursue chronic disease applications through neural data, with comparable hardware-software-AI integrated offerings.

TypeDirect peer
Description

Saluda Medical develops closed-loop neuromodulation devices (Evoke system) that use real-time neural feedback to personalize spinal cord stimulation. Closely aligned with BIOS's NeuroTune AI dosing platform philosophy of automating and personalizing neuromodulation parameters via neural signal analysis.

TypeDirect peer
Description

Setpoint Medical develops bioelectronic medicine targeting inflammatory diseases through vagus nerve stimulation. Highly comparable to BIOS's Autonomic Therapy Initiative (ATI) approach of using neural interfaces and AI to treat chronic inflammatory and autoimmune conditions.

TypeDirect peer
Description

Neuralink develops implantable brain-computer interfaces with AI-driven signal processing for medical and consumer applications. While Neuralink focuses on higher-bandwidth cortical interfaces and BIOS on peripheral/autonomic neural interfaces, both pursue the same fundamental vision of reading/writing neural code.

TypeBroad incumbent
Description

Medtronic is the largest neuromodulation device company with established vagus nerve stimulation, deep brain stimulation, and spinal cord stimulation franchises. BIOS's NeuroTune could either compete with or license into Medtronic's installed base, making Medtronic both a potential partner and competitor.

TypeBroad incumbent
Description

Boston Scientific (via LivaNova acquisition) offers Vagus Nerve Stimulation therapy for epilepsy and depression, directly overlapping BIOS's ATI therapeutic targets. As a broad incumbent, Boston Scientific has the regulatory, commercial, and clinical infrastructure to either compete with or partner with BIOS.

8Abbott
TypeBroad incumbent
Description

Abbott's neuromodulation division (formerly St. Jude Medical) markets Proclaim DRG and Prodigy MRI neurostimulation systems for chronic pain. As a broad incumbent with established hospital sales channels, Abbott could either license BIOS's AI dosing or compete with proprietary closed-loop capabilities.

TypeEmerging player
Description

Insitro uses AI/ML for drug discovery and development, addressing pharma R&D productivity similar to BIOS's clinical trial neural monitoring service. Both target pharmaceutical companies with AI-driven platforms, though Insitro focuses on in silico biology while BIOS focuses on neural signal interpretation.

TypeEmerging player
Description

Recursion uses AI/ML for high-throughput drug discovery and is building clinical trial optimization capabilities. While Recursion operates in a different therapeutic modality (small molecule + phenotypic screening), it overlaps with BIOS on AI-enabled clinical trial efficiency for pharma customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BIOS

Neural Engineering / Bioelectronic Medicine Softwarebios.health

BIOS Health is a UK-based neural engineering company that builds AI-driven neural interfaces and an AI dosing platform (NeuroTune) to read and write the body's nervous system signals in real time, serving pharmaceutical firms, neuromodulation device makers, healthcare providers, and academic medical centers.

What BIOS does

BIOS Health Ltd is a Cambridge, UK-based neural engineering company founded in 2015 by Cambridge University researchers Emil Hewage and Oliver Armitage. The company develops AI-driven neural interface technology that reads and writes the body's neural signals in real-time, with the stated goal of building "neural digital therapies" as a new class of precision medicine. Its core platform combines proprietary neural interfaces with machine learning, including Bayesian optimization (NeuroTune), neural biomarker discovery, and a Remote Health Platform that pairs wearables with mobile apps to capture cardiac and autonomic biomarkers. The technology is positioned as functionally analogous to DNA sequencing for the nervous system, supporting personalized neuromodulation dosing and software-delivered therapies for chronic cardiovascular, neurological, and metabolic conditions.

BIOS serves pharmaceutical companies, medical device manufacturers (particularly neuromodulation device makers), healthcare providers, and academic medical centers. Revenue is generated through long-term co-development partnerships (subscription/recurring), clinical trial data services (professional services), and licensing of the NeuroTune platform, with multi-year contracts and quote-based pricing disclosed as the standard engagement model. The company is supported by a deep research and grant ecosystem spanning NIH (REVEAL $21M project), SPARC-NIH ($1.4M grant plus Neuromod Prize), Canadian collaborations with Mila/McGill/Universit\u00e9 de Montr\u00e9al (cumulative CA$2.6M), the NHS, and a board chaired by IQVIA's VP of Genomic and Precision Medicine. Operationally, BIOS maintains hubs in Cambridge (headquarters), Montreal (AI R&D at Mila), and Bakersfield, California (US clinical and commercial hub established January 2024), and in 2026 spun out a majority-owned subsidiary, Kordata Dynamics, to commercialize an AI-powered precision clinical trials platform built on BIOS's NeuroTune IP.

BIOS firmographics

Firmographics
Name
BIOS
Legal name
BIOS Health Ltd
Website
https://bios.health
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
BIOS Health is a UK-based neural engineering company that builds AI-driven neural interfaces and an AI dosing platform (NeuroTune) to read and write the body's nervous system signals in real time, serving pharmaceutical firms, neuromodulation device makers, healthcare providers, and academic medical centers.
Ownership category
akta.pro rank

BIOS industry classification

Industry
Product category
Neural Engineering / Bioelectronic Medicine Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Neural digital therapies
  • Neuromodulation dosing AI
  • Bioelectronic medicine
  • Neural biomarker discovery
  • Autonomic therapy platform

Where BIOS is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

BIOS business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. Technology Partnerships with Pharma/MedTech: Long-term partnerships for co-development of neural digital therapies with pharmaceutical and medical device companies. BIOS technology enables real-time insights into how pharmaceuticals affect the nervous system, cutting feedback time on efficacy results from months to minutes.
  2. Clinical Trial Services: Providing neural data analysis services for clinical trials, enabling pharmaceutical companies to reduce trial timelines and improve success rates through real-time neural response monitoring.
  3. NeuroTune Platform Licensing: Making BIOS NeuroTune available to select clinical and preclinical partners for personalized dosing optimization of neuromodulation devices.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractEnterprise partnership model - custom pricing based on scope

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

BIOS product offering

Product offering

Core offering

BIOS Health develops an AI-driven neural interface platform that reads and writes nervous system signals in real-time to enable neural digital therapies. The company sells co-development partnerships, clinical trial data services, and licensing of its NeuroTune dosing AI platform to pharmaceutical, medical device, and clinical research partners, with a primary focus on autonomic and neuromodulation therapies for chronic diseases.

Differentiator

Problem solved

Functional benefit

Brands

  • NeuroTune: BIOS NeuroTune is the company's dosing AI co-pilot that personalizes neuromodulation device settings in under ten minutes. The algorithms dynamically model a patient or subject's neural and physiological responses to stimulations and suggest personalized parameters.
  • Autonomic Therapy Initiative (ATI)
  • Remote Health Platform (RHP)

Products and services

  • NeuroTune (Neural Dosing Platform) AI-powered dosing co-pilot that personalizes neuromodulation device settings in under 10 minutes. Dynamically models patient neural and physiological responses to stimulations and suggests personalized parameters. For researchers, accelerates therapy discovery by assessing thousands of unique stimulations in a single trial.
  • Neural Biomarker Discovery Platform Technology platform that precisely links nerve activity to specific chronic conditions by isolating neural biomarkers of disease and responding to them in real-time. Enables reading and writing the body's neural signals to understand and correct faulty signals causing disease.
  • Remote Health Platform (RHP) Medical device platform combining wearable devices and mobile apps to monitor patient health remotely. Collects biomarkers and cardiac metrics including ECG, PPG, accelerometer, respiratory pressure, and blood glucose data to deliver personalized and responsive neural digital therapies.
  • Autonomic Therapy Initiative (ATI) Programme initiative to develop neural digital therapies for cardiovascular diseases using AI-powered neural interfaces. Works with world-leading partners to deliver new treatments for heart disease through real-time neural signal analysis and closed-loop neuromodulation.
  • Clinical Trial Neural Data Services Service offering that provides neural data analysis for pharmaceutical clinical trials, enabling real-time neural response monitoring, adaptive dosing optimization, and reduced trial timelines by cutting efficacy feedback time from months to minutes.

Quantifiable outcome

  • Reduces neuromodulation device optimization from 12 months to under 10 minutes
  • +3 more outcomes

Companies that use BIOS

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

BIOS technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

BIOS partnerships and signals

Strategic signal

Partnerships

18 partnerships are on record, tiered core, minor and flagship.

  • City of BakersfieldcoreStrategic or Co-development Partner · 8 January 2024Partnered with KVG and Kern County to establish BIOS West Coast precision medicine hub. Approved $250K grant for BIOS to establish first US clinical and commercial hub.
  • Kern CountycoreStrategic or Co-development Partner · 8 January 2024Partnered with City of Bakersfield and KVG to attract BIOS to the region. Part of economic development initiative for biotech and AI sector growth.
  • Cal State BakersfieldminorStrategic or Co-development Partner · 22 June 2023Partnership to develop trained workers for BIOS precision medicine hub in Bakersfield.
  • National Institutes of Health (NIH)flagshipStrategic or Co-development Partner · 3 November 2022BIOS technology selected to power the $21M REVEAL project - the largest ever single clinical study of human neural data. BIOS provides software infrastructure for analyzing neural data from 150 patients across 8 global clinics over 3 years, investigating neural therapies for chronic diseases.
  • University of MinnesotaflagshipStrategic or Co-development Partner · 3 November 2022Lead institution for NIH REVEAL project. Principal Investigator John Osborn leads the consortium. Study focuses on vagus nerve physiology and neural therapies for cardiovascular, metabolic, immune, and autonomic nervous systems.
  • Mayo CliniccoreStrategic or Co-development Partner · 3 November 2022Clinical partner in REVEAL project, contributing to research on neural therapies for chronic diseases including heart failure, epilepsy, and respiratory conditions.
  • Stanford UniversitycoreStrategic or Co-development Partner · 3 November 2022Clinical partner in NIH REVEAL project, contributing expertise to neural biomarker research and vagus nerve stimulation therapies.
  • MUSC HealthminorStrategic or Co-development Partner · 3 November 2022Academic health system partner in REVEAL consortium for neural therapies research.
  • Washington University in St. LouisminorStrategic or Co-development Partner · 3 November 2022Academic partner in NIH REVEAL project consortium.
  • Sheppard PrattminorStrategic or Co-development Partner · 3 November 2022Mental health system partner in REVEAL project consortium.
  • Scuola Superiore Sant'Anna (Italy)minorStrategic or Co-development Partner · 3 November 2022European academic partner in REVEAL project for vagus nerve research.
  • Baker Heart and Diabetes InstituteminorStrategic or Co-development Partner · 3 November 2022Australian research partner in REVEAL consortium for neural-cardiac research.
  • Mila (Montreal AI Institute)coreStrategic or Co-development Partner · 26 May 2020BIOS opened R&D office at Mila in 2018 to leverage Montreal's AI talent. Partnership to develop AI-controlled closed-loop neuromodulation system for chronic cardiac conditions. Extended in 2022 with CA$1.8M funding.
  • McGill UniversitycoreStrategic or Co-development Partner · 26 May 2020Research partnership with Dr. Blake Richards (School of Computer Science) to use machine learning to identify relationships between cardiac activity and neural signals. Part of CA$800K and CA$1.8M initiatives.
  • Université de MontréalcoreStrategic or Co-development Partner · 26 May 2020Research partnership with Dr. Guillaume Lajoie (Applied Mathematics) to optimize neural interface system for decoding and encoding brain-to-body signals. Part of neuro-cardiology AI collaboration.
  • NVIDIAcoreTechnology or IntegrationNVIDIA GPUs used for BIOS AI and machine learning processing. Listed as selected partner on website footer.
  • NHScoreStrategic or Co-development PartnerUK National Health Service partnership for clinical trials. BIOS conducted remote trials with NHS during COVID-19 pandemic.
  • SPARC (Stimulating Peripheral Activity to Relieve Conditions)flagshipStrategic or Co-development PartnerNIH Common Fund program. Awarded BIOS $1.4M grant in 2021 and BIOS won $100K Neuromod Prize Phase 1. BIOS technology powers SPARC objectives for neural treatment development.

Scale indicators10 records

Recent moves9 records

Expansion highlights6 records

BIOS competitors and assessment

Company assessment

Direct peers

  • Synchron: Synchron develops brain-computer interface technology (Stentrode) for patients with paralysis, similar to BIOS's neural interface focus. Both target chronic disease through neural signal interpretation, though Synchron emphasizes motor restoration while BIOS targets therapy dosing and digital therapeutics.
  • Blackrock Neurotech: Blackrock Neurotech builds neural interface platforms for research and clinical applications, with similar focus on reading/writing neural signals. Both companies pursue chronic disease applications through neural data, with comparable hardware-software-AI integrated offerings.
  • Saluda Medical: Saluda Medical develops closed-loop neuromodulation devices (Evoke system) that use real-time neural feedback to personalize spinal cord stimulation. Closely aligned with BIOS's NeuroTune AI dosing platform philosophy of automating and personalizing neuromodulation parameters via neural signal analysis.
  • Setpoint Medical: Setpoint Medical develops bioelectronic medicine targeting inflammatory diseases through vagus nerve stimulation. Highly comparable to BIOS's Autonomic Therapy Initiative (ATI) approach of using neural interfaces and AI to treat chronic inflammatory and autoimmune conditions.
  • Neuralink: Neuralink develops implantable brain-computer interfaces with AI-driven signal processing for medical and consumer applications. While Neuralink focuses on higher-bandwidth cortical interfaces and BIOS on peripheral/autonomic neural interfaces, both pursue the same fundamental vision of reading/writing neural code.

Broad incumbents

  • Medtronic: Medtronic is the largest neuromodulation device company with established vagus nerve stimulation, deep brain stimulation, and spinal cord stimulation franchises. BIOS's NeuroTune could either compete with or license into Medtronic's installed base, making Medtronic both a potential partner and competitor.
  • Boston Scientific: Boston Scientific (via LivaNova acquisition) offers Vagus Nerve Stimulation therapy for epilepsy and depression, directly overlapping BIOS's ATI therapeutic targets. As a broad incumbent, Boston Scientific has the regulatory, commercial, and clinical infrastructure to either compete with or partner with BIOS.
  • Abbott: Abbott's neuromodulation division (formerly St. Jude Medical) markets Proclaim DRG and Prodigy MRI neurostimulation systems for chronic pain. As a broad incumbent with established hospital sales channels, Abbott could either license BIOS's AI dosing or compete with proprietary closed-loop capabilities.

Emerging players

  • Insitro: Insitro uses AI/ML for drug discovery and development, addressing pharma R&D productivity similar to BIOS's clinical trial neural monitoring service. Both target pharmaceutical companies with AI-driven platforms, though Insitro focuses on in silico biology while BIOS focuses on neural signal interpretation.
  • Recursion Pharmaceuticals: Recursion uses AI/ML for high-throughput drug discovery and is building clinical trial optimization capabilities. While Recursion operates in a different therapeutic modality (small molecule + phenotypic screening), it overlaps with BIOS on AI-enabled clinical trial efficiency for pharma customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

BIOS social profiles

Digital presence

BIOS financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BIOS leadership team

Management profile

Number of profiles

Profiles9 records

BIOS subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

BIOS funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BIOS M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BIOS

What does BIOS do?

BIOS Health develops an AI-driven neural interface platform that reads and writes nervous system signals in real-time to enable neural digital therapies. The company sells co-development partnerships, clinical trial data services, and licensing of its NeuroTune dosing AI platform to pharmaceutical, medical device, and clinical research partners, with a primary focus on autonomic and neuromodulation therapies for chronic diseases.

Is BIOS a public or private company?

BIOS is a private company. It is classified as venture growth investor backed and is currently operating.

When was BIOS founded?

BIOS was founded in 2015. It employs 11 to 50 people.

Where is BIOS based?

BIOS is headquartered in Cambridge, United Kingdom, in the Europe region.

How does BIOS make money?

Three revenue lines are on record. Technology Partnerships with Pharma/MedTech is the primary driver. The others are clinical Trial Services and neuroTune Platform Licensing.

Who are BIOS's main competitors?

Direct peers on record are Synchron, Blackrock Neurotech, Saluda Medical, Setpoint Medical and Neuralink. Broad incumbents are Medtronic, Boston Scientific and Abbott. Emerging players are Insitro and Recursion Pharmaceuticals.

Does BIOS have an API?

No public API is recorded for BIOS.

What industry is BIOS in?

BIOS's product category is Neural Engineering / Bioelectronic Medicine Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ForbesSmart Hands, Human Touch: Neurotech Tightens Grip On Robotics MarketPhantom Neuro and BIOS implanted neural interfaces in human participants to control smart prosthetic arms, with Phantom's first implantation in Australia and BIOS's trial participant demonstrating hand sensation. Both companies target upper-limb prosthetics as a first market, with commercial launch expected by 2028.Business Wire BlogKordata Dynamics Emerges From Stealth With Launch of AI Platform for Next-Generation Precision Clinical Trials and Backing From BIOS Health InvestorsKordata Dynamics emerged from stealth with the launch of an AI platform for precision clinical trials, backed by pre-seed funding from MAVRK Celestia Fund, Kern Venture Group, and Digital Neural Infrastructure Holdings, as a spin-out from BIOS Health. The company has positioned its inaugural site in Bakersfield, California, leveraging BIOS Health's proprietary NeuroTune AI precision dosing technology to target a $26 billion backlog in clinical trials, with an initial focus on precision neuromodulation and neural therapies. The launch coincided with the FDA's introduction of a pilot program for real-time clinical trials, positioning the company at a potential inflection point in US clinical trial innovation.FfnewsFSS Future-Proofs Middle East Payments with Scalable, Sovereign Cloud InfrastructureFinancial Software & Systems (FSS) announced the successful completion of a major cloud transformation initiative, migrating mission-critical customer platforms across the Middle East to a sovereign, enterprise-grade private cloud. The migration leverages geo-redundant Equinix datacenters in Dubai and Abu Dhabi, with BIOS Cloud (ZainTech) as the selected cloud service provider, ensuring all customer data is stored and processed exclusively within UAE territory in alignment with UAE Central Bank data residency mandates. This strategic modernization establishes a scalable and resilient foundation designed to support high-volume digital payments growth across Middle East financial institutions.GovtechCalifornia City Approves Grant to Support Neurotech StartupThe Bakersfield City Council unanimously approved a $250,000 grant for UK-based neuroscience startup BIOS Health to establish its first US clinical and commercial hub in the city. BIOS, which uses AI-enhanced neural scanning to develop medicines for conditions including epilepsy and cardiovascular diseases, plans to bring at least one groundbreaking clinical trial to Bakersfield by 2027, projecting over $100 million in economic impact per trial. The company is contributing $1.5 million in equipment and partnering with Cal State Bakersfield to develop trained workers for the precision medicine hub.MorningstarMYndspan and BIOS Health Partner to Make Consumer-Scale Precision Neuroscience a RealityMYndspan and BIOS Health announced a partnership to combine MYndspan's consumer MEG brain scans with BIOS Health's neural data and AI platform. The collaboration aims to make precision neuroscience more accessible, citing a study on brain aging markers. The companies seek to expand research findings into practical applications for consumers and clinicians.YahooMYndspan and BIOS Health Partner to Make Consumer-Scale Precision Neuroscience a RealityMYndspan and BIOS Health announced a partnership to combine MYndspan's consumer MEG brain scans with BIOS Health's neural data and AI platform. The collaboration aims to make precision neuroscience more accessible, citing a study on brain aging markers. The companies seek to expand research findings into practical applications for consumers and clinicians.Business & FinancialMyndspan And BIOS Health Partner To Make Consumer-Scale Precision Neuroscience A RealityMYndspan and BIOS Health announced a partnership to combine MYndspan's consumer MEG brain scans with BIOS Health's neural data and AI platform. The collaboration aims to make precision neuroscience more accessible, with a study cited showing MYndspan's ability to identify markers of healthy and accelerated brain aging.PR NewswireMYndspan and BIOS Health Partner to Make Consumer-Scale Precision Neuroscience a RealityMYndspan and BIOS Health announced a partnership to combine MYndspan's consumer MEG brain scans with BIOS Health's neural data and AI platform. The collaboration aims to make precision neuroscience more accessible, building on a study that identified markers of healthy and accelerated brain aging.Business Wire BlogBIOS Health Plans State-of-the-Art Precision Medicine Center in Bakersfield, CaliforniaBIOS Health announced a partnership with the City of Bakersfield, Kern County, and Kern Venture Group to build a precision medicine center in Bakersfield, California. The center will focus on neural digital therapies and real-time neural insights, aiming to reduce clinical trial failure rates. It will be BIOS's second international hub, following a Montreal site.